SuspendedPhase 2NCT06069375
Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Studying Acyl-CoA dehydrogenase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jerry Vockley, MD, PhD
- Principal Investigator
- Gerard L Vockley, MD, PhDUPMC Children's Hospital of Pittsburgh
- Intervention
- Sodium phenylbutyrate(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 10 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Collaborators
Acer Therapeutics Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06069375 on ClinicalTrials.govOther trials for Acyl-CoA dehydrogenase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07097311Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)Jerry Vockley, MD, PhD
- RECRUITINGPHASE2NCT06773026Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)Jerry Vockley, MD, PhD
- RECRUITINGNANCT06623032Metabolic Effects of Medium-Chain Fatty Acids in Patients With Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Healthy IndividualsUniversity of Copenhagen